Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 12,253 Shares

Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett sold 12,253 shares of Immunovant stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $29.06, for a total value of $356,072.18. Following the completion of the sale, the chief financial officer now directly owns 359,456 shares of the company’s stock, valued at approximately $10,445,791.36. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Eva Renee Barnett also recently made the following trade(s):

• On Tuesday, April 9th, Eva Renee Barnett sold 3,689 shares of Immunovant stock. The stock was sold at an average price of $31.18, for a total value of $115,023.02.
• On Thursday, February 22nd, Eva Renee Barnett sold 2,930 shares of Immunovant stock. The stock was sold at an average price of $36.15, for a total value of $105,919.50.

Immunovant Trading Down 0.4 %

NASDAQ:IMVT opened at $28.22 on Friday. Immunovant, Inc. has a 12 month low of $15.08 and a 12 month high of $45.58. The business’s 50-day moving average is $33.00 and its 200 day moving average is $36.05.

Immunovant (NASDAQ:IMVT) last released its earnings results on Monday, February 12th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. On average, equities analysts predict that Immunovant, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Truist Financial reissued a “buy” rating and issued a $48.00 target price on shares of Immunovant in a report on Monday, March 25th. The Goldman Sachs Group initiated coverage on Immunovant in a report on Wednesday, March 13th. They issued a “buy” rating and a $50.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunovant in a report on Friday, January 12th. JPMorgan Chase & Co. initiated coverage on Immunovant in a report on Tuesday, February 20th. They issued an “overweight” rating and a $51.00 price objective for the company. Finally, Wolfe Research initiated coverage on Immunovant in a report on Thursday, February 15th. They issued an “outperform” rating and a $55.00 price objective for the company. Seventeen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunovant currently has an average rating of “Buy” and a consensus target price of $48.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IMVT. Point72 Asset Management L.P. bought a new position in shares of Immunovant during the fourth quarter valued at approximately $112,356,000. FMR LLC boosted its holdings in shares of Immunovant by 47.5% in the third quarter. FMR LLC now owns 7,748,546 shares of the company’s stock valued at $297,467,000 after purchasing an additional 2,494,678 shares during the period. Federated Hermes Inc. boosted its holdings in shares of Immunovant by 281.2% in the first quarter. Federated Hermes Inc. now owns 1,903,894 shares of the company’s stock valued at $10,491,000 after purchasing an additional 1,404,404 shares during the period. Octagon Capital Advisors LP boosted its holdings in shares of Immunovant by 127.3% in the fourth quarter. Octagon Capital Advisors LP now owns 273,289 shares of the company’s stock valued at $11,514,000 after purchasing an additional 1,273,289 shares during the period. Finally, Fred Alger Management LLC boosted its holdings in shares of Immunovant by 6,108.9% in the third quarter. Fred Alger Management LLC now owns 1,186,031 shares of the company’s stock valued at $45,532,000 after purchasing an additional 1,166,929 shares during the period. Institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.